2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow ART5803: new trials by email Literature Review of ART5803 trials Research Report on ART5803
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease ART5803, ART5803-Cohort D - Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease | Phase 2 | Recruiting | Arialys Australia Pty Ltd | 30 | 2026-05-15 | 2026-10-27 |
| Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants ART5803, Intravenous immunoglobulin (IVIG) - Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder) | Phase 1 | Completed | Arialys Therapeutics | 7 | 2025-02-25 | 2026-04-27 |
| Phase 1 Study of ART5803 in Healthy Participants ART5803 - Autoimmune Encephalitis | Phase 1 | Completed | Arialys Therapeutics | 64 | 2024-09-19 | 2026-04-27 |
Autoimmune Diseases of the Nervous System (3) · Encephalitis (3)
Arialys Therapeutics (2) · Arialys Australia Pty Ltd (1)
Australia (2) · South Korea (1)
Sankalp Gokhale, MD, MBA (2) · Pete Flynn, PhD (1)